In the last trading session, 59.74 million Recursion Pharmaceuticals Inc (NASDAQ:RXRX) shares changed hands as the company’s beta touched 0.83. With the company’s per share price at $5.49 changed hands at $0.92 or 20.13% during last session, the market valuation stood at $2.23B. RXRX’s last price was a discount, traded about -125.14% off its 52-week high of $12.36. The share price had its 52-week low at $3.79, which suggests the last value was 30.97% up since then.
Analysts gave the Recursion Pharmaceuticals Inc (RXRX) stock a consensus recommendation rating of Buy, calculated at a mean rating of 2.43. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended RXRX as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight. Recursion Pharmaceuticals Inc’s EPS for the current quarter is expected to be -0.36.
Recursion Pharmaceuticals Inc (NASDAQ:RXRX) trade information
Instantly RXRX was in green as seen at the end of in last trading. With action 31.34%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -18.79%, with the 5-day performance at 31.34% in the green. However, in the 30-day time frame, Recursion Pharmaceuticals Inc (NASDAQ:RXRX) is 31.03% up.
The consensus price target for the stock as assigned by Wall Street analysts is 6, meaning bulls need an upside of 8.5% from its current market value. According to analyst projections, RXRX’s forecast low is 6 with 6 as the target high. To hit the forecast high, the stock’s price needs a -9.29% plunge from its current level, while the stock would need to soar -9.29% for it to hit the projected low.
Recursion Pharmaceuticals Inc (RXRX) estimates and forecasts
Year-over-year growth is forecast to reach 28.88% up from the last financial year.
Consensus estimates given by 6 financial analysts project the company’s revenue in the current quarter to hit an average of 16.23M. 6 analysts are of the opinion that Recursion Pharmaceuticals Inc’s revenue for the current quarter will be 20.47M. The company’s revenue for the corresponding quarters a year ago was 14.42M and 26.08M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 12.60%. The estimates for the next quarter sales put growth at -21.53%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -35.28%. The 2025 estimates are for Recursion Pharmaceuticals Inc earnings to increase by 15.09%, but the outlook for the next 5-year period is at 19.85% per year.
RXRX Dividends
Recursion Pharmaceuticals Inc is expected to release its next quarterly earnings report in July.
BAILLIE GIFFORD & CO holds the second largest percentage of outstanding shares, with 10.9787% or 26.59 million shares worth $199.42 million as of 2024-06-30.
Among Mutual Funds, the top two as of Apr 30, 2025 were ARK ETF Trust-ARK Innovation ETF and ARK ETF Trust-ARK Genomic Revolution ETF . With 18.65 shares estimated at $102.4 million under it, the former controlled 4.67% of total outstanding shares. On the other hand, ARK ETF Trust-ARK Genomic Revolution ETF held about 2.95% of the shares, roughly 11.78 shares worth around $64.66 million.
